| Code | CSB-RA019049MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Apamistamab, targeting PTPRC (Protein Tyrosine Phosphatase Receptor Type C), also known as CD45. PTPRC is a transmembrane glycoprotein exclusively expressed on all nucleated hematopoietic cells, functioning as a critical regulator of antigen receptor signaling in T and B lymphocytes. This receptor-like protein tyrosine phosphatase plays essential roles in immune cell development, activation, and differentiation by modulating Src family kinase activity. Dysregulation of PTPRC expression and function has been implicated in various hematological malignancies, autoimmune disorders, and severe combined immunodeficiency syndromes.
Apamistamab represents a therapeutic antibody developed for targeting CD45-positive hematological cancers, particularly in the context of conditioning regimens for hematopoietic stem cell transplantation. This biosimilar provides researchers with a valuable tool for investigating immune cell biology, studying lymphocyte signaling pathways, and exploring mechanisms underlying blood cancers and immunological diseases. It enables comprehensive research into PTPRC-mediated cellular processes and supports the development of novel immunotherapeutic strategies.
There are currently no reviews for this product.